Skip to main content

26-07-2018 | Scleroderma | Article

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial

Sircar G et al. Rheumatology (Oxford) 2018: key213. doi: 10.1093/rheumatology/key213

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

Related topics

EULAR 2020 E-Congress hub

Access the latest news and expert video commentary from the EULAR 2020 E-Congress.

Image Credits